- Revenue was at Rs 1,657 Crore versus Rs 1,591 Crore in Q2'FY21
- Reported EBITDA at Rs 344 Crore versus Rs 353 Crore in Q2'FY21
- Finance costs at Rs 35 Crore vs. Rs 46 Crore in Q2'FY21
- PAT was at Rs 143 Crore as compared with Rs 147 Crore in Q2'FY21
- EPS is Rs 8.97 versus Rs 9.21 in Q2'FY21
- Capital expenditure for the quarter was Rs 131 Crore
Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova said: “The Company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment. In the Pharmaceuticals segment, while Radiopharma, Allergy and CMO businesses reported growth on a YoY basis, the API business’ performance was lower on a higher base last year and Generics business witnessed headwinds due to temporary pricing pressure in the US market. The Generics business was also affected during the quarter by the Import Alert at the Roorkee plant and by impact of the Industry wide impurity issue in certain sartan products that led to lower sales and some product withdrawal.
In our Contract Research and Development Services business, we witnessed strong growth both YoY and sequentially driven by continued strong demand from our customers for our Drug Discovery Services.
In the Proprietary Novel Drugs business, our plans are on track to take one program to the clinical stage by end of this financial year.
During H1’FY22, we grew our revenues by 20% YoY and improved our EBITDA margins by 2.44% vs. H1’FY21 due to recovery in Radiopharma business and strong performance in Allergy Immunotherapy, CMO, API and Contract Research businesses.
I would like to mention that over the medium term, we have very strong growth levers in all our businesses. To drive growth in these businesses, Company will continue to invest accordingly.”